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Lung cancer screening with low-dose Computed Tomography signature. The cohorts were recruited from different health centers
(LDCT) was recently shown to be effective in reducing lung cancer
mortality (Aberle et al., 2011). An ~20% of reduction of mortality was
observed at 3 years in the LDCT arm of a randomized multicenter
study, the National Lung Cancer Screening Trial (NLST), which enrolled
~53.000 high-risk individuals (N55 years, N30 packs-year) planned to
receive annual LDCT or chest X-ray (Aberle et al., 2011). This ground-
breaking result occurred after several years of debate about the beneﬁts
of LDCT screening in terms of improved early diagnosis and survival,
and whether an annual LDCT scan in asymptomatic high-risk individ-
uals should be recommended or not (Field and Duffy, 2008). However,
both the high number of individuals who need to be screened to detect
one lung cancer patient (~1 patient out of 100 individuals) and the size-
able false-positive rate of LDCT observed in these screening trials (most
of the lung nodules detected are benign, ~96%) are limiting the wide-
spread applicability of LDCT screening programs (Aberle et al., 2011).
Therefore, there is an urgent need to identify novel biomarkers for the
early diagnosis of lung cancer to better identify thehigh-risk population,
thus reducing the number of unnecessary LDCTs for individualswithout
lung cancer and the rate of false-positive ﬁndings.
In this issue of EBioMedicine,Wang et al. (2015) describes a new set of
biomarkers diagnostic for lung cancer. The authors found that the
increased serum levels of 5 microRNAs (miR-483-5p, miR-193a-3p,
miR-25, miR-214 and miR-7) in a Chinese cohort of lung cancer patients
and healthy individuals were diagnostic for lung cancer. MicroRNAs
(miRNAs) are short non-coding RNA molecules involved in the regula-
tion of many cellular processes by acting as endogenous triggers of the
mRNA interference pathway (Krol et al., 2010). Importantly, ﬂuctuations
of circulatingmiRNAswere shown to be associatedwithmanymalignant
and non-malignant diseases, including lung cancer (Chen et al., 2008). Of
note, circulating miRNAs are remarkably stable in the blood despite
harsh conditions due to the presence of high levels of RNases (Mitchell
et al., 2008). Therefore, circulating miRNAs appear to be excellent candi-
dates for blood-borne tumor markers for the diagnosis of cancer.
An important aspect in the present study byWang et al. is the exten-
sive validation of these miRNA biomarkers in independent cohorts of
patients. Indeed, the authors used four independent cohorts of patients
and healthy individuals (for a total of 221 NSCLC, 56 with benign nod-
ules, and 161 healthy individuals) to train and validate the 5-miRNADOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.07.034.
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(Chinese and American individuals) to appreciate eventual differences
in the basal blood miRNA level, which could negatively affect the diag-
nostic test performance. These are all very important aspects that
should be taken in consideration when designing a screening study
for cancer biomarker identiﬁcation. Indeed, the failure of many pro-
posed cancer biomarkers once validated in clinical trials is mainly as-
cribable to a poor study design adopted during the discovery phase,
which, in most of the cases, did not include cohorts of patients sufﬁ-
ciently large and independent (Poste, 2011).
Other research groups have recently described circulating miRNA
signatures in serum and plasma for the early diagnosis of lung cancer,
with comparable results in terms of sensitivity and speciﬁcity for detect-
ing lung cancer (Sozzi et al., 2014; Montani et al., 2015; Wozniak et al.,
2015). Some of these signatures have been already validated in existing
lung cancer screening studies (Sozzi et al., 2014; Montani et al., 2015),
which is mandatory to assess the accuracy of these diagnostic bio-
markers in detecting asymptomatic early-stage lung cancer. It would
be interesting to perform a meta-analysis of all of these signatures by
using both serum and plasma samples from the same cohort of individ-
uals. This would allow the direct comparison of their diagnostic perfor-
mance and, eventually, identify a core of biomarkers to increase the
overall accuracy of a miRNA-based test for lung cancer early detection.
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